CD274 and neoplasm: While 2FF treatment alone did not significantly impact tumor growth, it significantly sensitized both HR-proficient (UPK10 and KPCA) and HR-deficient (BPPNM and HGS2) tumors to anti-PD-L1 immunotherapy (Fig. 2f, g).